Income Statement Eiger BioPharmaceuticals
Stocks
EIGR
US28249U2042
Biotechnology & Medical Research
|
Market Closed -
OTC Markets
11:27:07 2024-09-27 EDT
|
5-day change | 1st Jan Change | ||
| 8.500 USD | -.--% |
|
-.--% | - |
| 24-10-01 | Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect | CI |
| 24-09-30 | Eiger BioPharmaceuticals, Inc. Went Out of Business | CI |
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | - | - | 12.14M | 12.73M | 15.52M | |||||
Other Revenues, Total | - | - | - | 750K | 250K | |||||
Total Revenues | - | - | 12.14M | 13.48M | 15.77M | |||||
Cost of Goods Sold, Total | - | - | 745K | 1.84M | 24K | |||||
Gross Profit | - | - | 11.4M | 11.65M | 15.75M | |||||
Selling General & Admin Expenses, Total | 17.11M | 20.56M | 23.9M | 29.1M | 25.2M | |||||
R&D Expenses | 51.79M | 41.59M | 64.44M | 75.28M | 62.33M | |||||
Other Operating Expenses, Total | 68.9M | 62.15M | 88.34M | 104M | 87.54M | |||||
Operating Income | -68.9M | -62.15M | -76.94M | -92.74M | -71.79M | |||||
Interest Expense, Total | -3.41M | -3.59M | -3.56M | -4.13M | -5.47M | |||||
Interest And Investment Income | 2.07M | 704K | 158K | 1.08M | 2.21M | |||||
Net Interest Expenses | -1.33M | -2.89M | -3.4M | -3.05M | -3.26M | |||||
Other Non Operating Income (Expenses) | -15K | -12K | 46.49M | 137K | 87K | |||||
EBT, Excl. Unusual Items | -70.25M | -65.05M | -33.85M | -95.65M | -74.96M | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Other Unusual Items | - | - | - | -1.1M | - | |||||
EBT, Incl. Unusual Items | -70.25M | -65.05M | -33.85M | -96.75M | -74.96M | |||||
Income Tax Expense | - | - | 64K | 23K | 6K | |||||
Earnings From Continuing Operations | -70.25M | -65.05M | -33.92M | -96.78M | -74.96M | |||||
Net Income to Company | -70.25M | -65.05M | -33.92M | -96.78M | -74.96M | |||||
Net Income - (IS) | -70.25M | -65.05M | -33.92M | -96.78M | -74.96M | |||||
Net Income to Common Incl Extra Items | -70.25M | -65.05M | -33.92M | -96.78M | -74.96M | |||||
Net Income to Common Excl. Extra Items | -70.25M | -65.05M | -33.92M | -96.78M | -74.96M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -92.5 | -69.34 | -29.98 | -69.74 | -50.78 | |||||
Basic EPS - Continuing Operations | -92.5 | -69.34 | -29.98 | -69.74 | -50.78 | |||||
Basic Weighted Average Shares Outstanding | 760K | 938K | 1.13M | 1.39M | 1.48M | |||||
Net EPS - Diluted | -92.5 | -69.34 | -29.98 | -69.74 | -50.78 | |||||
Diluted EPS - Continuing Operations | -92.5 | -69.34 | -29.98 | -69.74 | -50.78 | |||||
Diluted Weighted Average Shares Outstanding | 760K | 938K | 1.13M | 1.39M | 1.48M | |||||
Normalized Basic EPS | -57.81 | -43.34 | -18.7 | -43.08 | -31.73 | |||||
Normalized Diluted EPS | -57.81 | -43.34 | -18.7 | -43.08 | -31.73 | |||||
Supplemental Items | ||||||||||
EBITDA | -68.84M | -61.98M | -76.66M | -92.45M | -71.51M | |||||
EBITA | -68.9M | -62.15M | -76.94M | -92.74M | -71.79M | |||||
EBIT | -68.9M | -62.15M | -76.94M | -92.74M | -71.79M | |||||
EBITDAR | -68.14M | -61.28M | -75.96M | -91.75M | - | |||||
Total Revenues (As Reported) | - | - | - | 13.48M | 15.77M | |||||
Effective Tax Rate - (Ratio) | - | - | -0.19 | -0.02 | -0.01 | |||||
Current Foreign Taxes | - | - | - | - | 6K | |||||
Total Current Taxes | - | - | - | - | 6K | |||||
Normalized Net Income | -43.91M | -40.66M | -21.16M | -59.78M | -46.85M | |||||
Interest on Long-Term Debt | 3.41M | 3.59M | 3.56M | 4.13M | 5.47M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 17.11M | 20.56M | - | - | - | |||||
Research And Development Expense From Footnotes | 51.79M | 41.59M | 64.44M | 75.28M | 62.33M | |||||
Net Rental Expense, Total | 700K | 700K | 700K | 700K | - | |||||
Imputed Operating Lease Interest Expense | 659K | 622K | 613K | 636K | - | |||||
Imputed Operating Lease Depreciation | 40.75K | 78.42K | 87.26K | 63.77K | - | |||||
Stock-Based Comp., R&D Exp. (Total) | 1.78M | 1.71M | 2.47M | 3.18M | 2.39M | |||||
Stock-Based Comp., G&A Exp. (Total) | 4.13M | 4.48M | - | - | - | |||||
Stock-Based Comp., SG&A Exp. (Total) | - | - | 5.65M | 5.16M | 2.62M | |||||
Total Stock-Based Compensation | 5.9M | 6.19M | 8.12M | 8.34M | 5.01M |
- Stock Market
- Stocks
- EIGR Stock
- Financials Eiger BioPharmaceuticals
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















